True facts19 Oct 2024 19:55
The dx sale is relevant but not massive in the grand scheme of things
The odd million will give Avacta more breathing space but this is only gonna play out 1 of 2 ways in my utterly brain dead monged opinion
1:everything fails (happens often in biotech)and we are between 20p and 40p a share ish
2:everything is looking fantastic and we get bought or a big licence deal
Simples
Make no mistake if they are shrinking tumours and keeping dead people alive in the latter part of this trial the increase in share price will be like no other .
I’m sure we can all agree on that
Worth a big risk from the 50p-70p range
No brainer